Results 1 to 10 of about 200,495 (117)

Effect of the Concomitant Use of Subcutaneous Basal Insulin and Intravenous Insulin Infusion in the Treatment of Severe Hyperglycemic Patients [PDF]

open access: yesEndocrinology and Metabolism, 2022
Background No consensus exists regarding the early use of subcutaneous (SC) basal insulin facilitating the transition from continuous intravenous insulin infusion (CIII) to multiple SC insulin injections in patients with severe hyperglycemia other than ...
Yejee Lim   +12 more
doaj   +1 more source

Effect of basal insulin therapy with glargine U300 versus basal bolus insulin therapy in hospitalized patients with type 2 diabetes. Real-world study from India

open access: yesClinical Diabetology, 2021
Background. Basal-bolus insulin therapy is the most widely accepted method of glycemic control in non-critically ill patients with T2DM. In this regimen glargine U100 is the most commonly used basal insulin.
Asis Mitra, Saswati Ray, Sushma Jayan
doaj   +1 more source

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?

open access: yesClinical Medicine Insights: Endocrinology and Diabetes, 2012
The advances in recombinant DNA technology have led to an improvement in the properties of currently available long-acting insulin analogs. Insulin degludec, a new generation ultra-long-acting basal insulin, currently in phase 3 clinical trials, has a ...
Sami N. Nasrallah, L. Raymond Reynolds
doaj   +2 more sources

Basal Insulin Reduces Glucose Variability and Hypoglycaemia Compared to Premixed Insulin in Type 2 Diabetes Patients: A Study Based on Continuous Glucose Monitoring Systems

open access: yesFrontiers in Endocrinology, 2022
AimsTo examine the glycaemic variability and safety of basal and premixed insulin by using continuous glucose monitoring (CGM) systems.Methods393 patients with type 2 diabetes mellitus (T2DM) treated with basal or premixed insulin for more than 3 months ...
Huiying Wang   +9 more
doaj   +1 more source

基于多中心前瞻性真实世界数据的基础胰岛素和预混合胰岛素对2型糖尿病患者血糖控制的影响研究

open access: yesJournal of Diabetes, 2022
Background To investigate the different efficacies of glycemic control between basal and premixed insulin in participants with type 2 diabetes (T2DM) when non‐insulin medications fail to reach treatment targets.
Ying Peng   +15 more
doaj   +1 more source

Effect of Insulin Plant (Costus igneus) Leaf Powder in Broiler Chickens (Gallus galluus domisticus)

open access: yesDiversitas Journal, 2023
This experiment was conducted to evaluate the effects of insulin plant leaf powder in broiler chickens. One hundred (100) chicks of the same age and random sexes were purchased from the local agrivet supplier and were used in the study.
Carla M Bagunoc   +2 more
doaj   +1 more source

Basal Insulin Analogues

open access: yesEndocrinology Research and Practice, 2022
-
Olcay Gedik
doaj   +2 more sources

Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns

open access: yesFrontiers in Endocrinology, 2021
Insulin degludec/insulin aspart (IDegAsp) is a fixed-ratio co-formulation of insulin degludec (IDeg), which provides long-lasting basal insulin coverage, and insulin aspart (IAsp), which targets post-prandial glucose. This expert panel aimed to provide a
Tevfik Demir   +5 more
doaj   +1 more source

Dulaglutide as an Effective Replacement for Prandial Insulin in Kidney Transplant Recipients with Type 2 Diabetes Mellitus: A Retrospective Review [PDF]

open access: yesDiabetes & Metabolism Journal, 2021
Dulaglutide, a weekly injectable glucagon-like peptide-1 receptor agonist, has demonstrated effectiveness when combined with basal insulin. We examined whether the efficacy of dulaglutide is comparable to that of prandial insulin in kidney transplant (KT)
Hwi Seung Kim   +4 more
doaj   +1 more source

Degludec insulin: A novel basal insulin

open access: yesIndian Journal of Endocrinology and Metabolism, 2011
This paper reviews a novel insulin analogue, degludec, which has the potential to emerge as an ideal basal insulin. It reviews the limitations of existing basal insulin and analogues, and highlights the need for a newer molecule.
Sanjay Kalra   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy